"rationale","uuid:ID","name","instanceType","label","id","description"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","7b5ef481-4d32-432d-ac6f-bbb13d7d872d","Study Design 1","StudyDesign","","StudyDesign_1","The main design for the study"
